Haemoglobin value and red blood cell transfusions in prolonged weaning from mechanical ventilation: a retrospective observational study

Sebastian Johannes Fritsch,1 Michael Dreher,2 Tim-Philipp Simon,1 Gernot Marx,1 Johannes Bickenbach1

ABSTRACT

Introduction The role of haemoglobin (Hb) value and red blood cell (RBC) transfusions in prolonged weaning from mechanical ventilation (MV) is still controversial. Pathophysiological considerations recommend a not too restrictive transfusion strategy, whereas adverse effects of transfusions are reported. We aimed to investigate the association between Hb value, RBC transfusion and clinical outcome of patients undergoing prolonged weaning from MV.

Methods We performed a retrospective, single-centred, observational study including patients being transferred to a specialised weaning unit. Data on demographic characteristics, comorbidities, current and past medical history and the current course of treatment were collected. Weaning failure and mortality were chosen as primary and secondary endpoint, respectively. Differences between transfused and non-transfused patients were analysed. To evaluate the impact of different risk factors including Hb value and RBC transfusion on clinical outcome, a multivariate logistic regression analysis was used.

Results 184 patients from a specialised weaning unit were analysed, of whom 36 (19.6%) failed to be weaned successfully. In-hospital mortality was 18.5%. 90 patients (48.9%) required RBC transfusion during the weaning process, showing a significantly lower Hb value (g/L) (86.3±5.3) than the non-transfusion group (95.8±10.5). In the multivariate regression analysis (OR 3.24; p=0.045), RBC transfusion was associated with weaning failure. However, the transfusion group had characteristics indicating that these patients were still in a more critical state of disease.

Conclusions In our analysis, the need for RBC transfusion was independently associated with weaning failure. However, it is unclear whether the transfusion itself should be considered an independent risk factor or an additional symptom of a persistent critical patient condition.

INTRODUCTION

In a majority of patients, mechanical ventilation (MV) can be discontinued without any relevant problems. Contrarily, approximately 15% of patients show a so-called prolonged weaning from MV due to several reasons. This particular patient group requires complex, multimodal, multiprofessional and protracted concepts and should be treated in specialised weaning centres.3 One aspect potentially impairing the weaning process is anaemia, which is a common phenomenon in nearly all patients after prolonged treatment on an intensive care unit (ICU).3 Anaemia of critical illness has a multifactorial pathogenesis, including haemodilution, (partly iatrogenic) blood loss, reduced red cell survival and production, abnormal iron metabolism,
The role of the haemoglobin (Hb) value and the impact of red blood cell (RBC) transfusions in prolonged weaning has been controversial for years. To the best of our knowledge, no randomised clinical trials with a relevant number of patients have addressed this issue so far. From a pathophysiological point of view, there are good reasons to argue for higher Hb values or a more liberal transfusion strategy. The rationale of an RBC transfusion with the intended increase of Hb concentration is the increase of the arterial oxygen content (C\(_{\text{aO}_2}\)) in order to improve the global and cellular oxygen delivery (DO\(_2\)) and to consecutively increase the cellular oxygen consumption (VO\(_2\)). Since DO\(_2\) is the product of C\(_{\text{aO}_2}\) and cardiac output, an increase of C\(_{\text{aO}_2}\) would unburden the cardiac system. However, the critical threshold for DO\(_2\), below which tissue hypoxia develops, varies individually and is difficult to determine precisely, even more in patients under prolonged weaning. In these patients, there is usually no tissue hypoxia during MV phases securing a sufficient gas exchange, while this can change considerably under spontaneous breathing. Anaemia can lead to increased cardiac output with consecutive additional load on the respiratory system. This is especially disadvantageous in prolonged weaning since these patients frequently show an insufficiency of respiratory musculature as well as of cardiac function. Compensation of anaemia can lead to a decrease in total oxygen consumption, since oxygen demand of both organs is increased in anaemia. Contrarily, there is growing evidence that an uncritical, liberal strategy in RBC transfusions has several disadvantages including nosocomial infections, but also immunological reactions up to a lung injury. Moreover, there is still controversy about Hb thresholds for transfusion to compensate anaemia-conditioned burden of ventilatory and/or cardiac load.

The objective of our study was to describe the clinical practice regarding RBC transfusions in a specialised weaning unit. We aimed to examine possible effects that could derive from Hb value or RBC transfusions onto the outcome represented by weaning success and hospital mortality in patients undergoing prolonged weaning from MV.

**METHODS**

**The weaning unit**

The interdisciplinary weaning unit (referred to as WEA) of the University Hospital RWTH Aachen, Germany consists of 18 beds and is equipped to provide full organ support (ie, invasive and non-invasive ventilation (NIV), intermittent dialysis, vasopressor therapy). It is run by a team of certified physicians, certified nurses, physiotherapists, respiratory therapists, as well as one speech therapist and one psychologist. Patients are referred from surgical and medical in-house ICUs, but also from external hospitals. Admission criteria include the absence of acute illness and multi organ failure, absence of high-dosage or multiple vasopressor therapy and absence of continuous renal replacement therapy (RRT). The surgical treatment, especially multi-stage procedures that require repeated performance of general anaesthesia, should be preferably completed prior to admission. An already performed tracheostomy not shorter than 24 hours and a documented spontaneous breathing trial (SBT) (including reasons for withdrawal) as well as consideration of assessing readiness to wean, respectively, on the ICUs were further admission criteria for the weaning unit. The weaning is carried out systematically according to the German S2k-guideline ‘Prolonged Weaning’.

Weaning subcategories according to the German S2k-guideline for prolonged weaning are defined as follows:

- 3a: Successful weaning after at least three failed SBT or MV longer than 7 days after the first failed SBT without the use of NIV.
- 3b: Successful weaning after at least three failed SBT or MV longer than 7 days after the first failed SBT in combination with NIV; if necessary, continued into out-of-hospital (home) MV.
- 3c: Weaning failure: indication for permanent, invasive home ventilation or death during the process of prolonged weaning.

**RBC transfusion guidelines**

Indication for RBC transfusion was made according to the German guideline for prolonged Weaning. According to this guideline, transfusions can be considered below a Hb value of 100 g/L considering patient’s risk factors, like certain comorbidities or physiological transfusion triggers, for example, tachycardia. The target Hb value should be between 70 and 90 g/L. If clinical symptoms indicate inadequate compensation for low Hb levels or significantly increased work of breathing (in severe lung disease) hampering successful weaning, the Hb value should be raised, at least over a value of 80 g/L. These recommendations are congruent with international guidelines as well. On WEA, the decision for RBC transfusion is made by the physician in charge at his clinical discretion. There are no additional local policies beyond the respective Guideline. Naturally, factors such as the patient’s cardiac situation or the clinical impression of an increased work of breathing were included into the clinical reasoning for or against an RBC transfusion.

**Study design and patient selection**

This study was a retrospective, single-centred, observational study. We used the Strengthening the Reporting of Observational Studies in Epidemiology case-control checklist when writing our report. We included all patients with prolonged weaning group 3 being transferred to the WEA in the year 2016 from another ICU of our university hospital. Patients transferred from an
external hospital with incomplete data or information about the preceding treatment and those admitted from an external care facility for a therapy check-up or a further weaning attempt were excluded. Patients discharged to a specialised rehabilitation centre with the aim to continue the weaning process there were excluded as well. A flow chart of exclusion process is indicated in figure 1. If a patient had more than one distinct stay on WEA, the final stay allowing a clear classification of weaning outcome was chosen.

**Patient and public involvement**

Due to the retrospective characteristics of this study, no patients were involved in setting the research question, the outcome measures, or the design or carrying out of the study. The result of the study will be disseminated publicly via conference presentations and publication in an open-access journal.

**Data collection**

Patient data were retrieved from an electronic patient record system (medico//s, Siemens, Germany) and from an online patient data documentary system (IntelliSpace Critical Care and Anesthesia, ICCA Rev. F.01.01.001, Philips Electronics, Netherlands). The information on RBC transfusions was taken from the documentation system of the hospital’s Department of Transfusion Medicine (Lauris, Nexus Swisslab, Berlin, Germany). Acquired data consisted of demographic data, comorbidities, length of stay, duration of MV, number of RBC transfusions, Hb values on admission and as mean value throughout the stay, information regarding medication and RRT. The Simplified Acute Physiology Score II (SAPS II) and the Therapeutic Intervention Scoring System (TISS) were acquired on admission. Although all patients had a continuous hospital stay, the stay in the ICU, which preceded the WEA treatment, was partly collected and analysed separately. Anaemia was defined according to the WHO definition using a cut-off value of Hb <130 g/L in males and <120 g/L in females, respectively.

**Statistical analysis**

Statistical analysis was carried out using SAS V.9.4. Continuous variables were expressed as mean value and SD. For comparison between subcohorts of transfused and non-transfused patients, the difference in means:CI for continuous variables and the OR ±CI for categorical variables (where applicable) was used. Weaning failure, that is, a weaning classification of 3b and 3c, was defined as the primary endpoint. As a secondary endpoint, hospital mortality was chosen. To evaluate the influence of RBC transfusions or the number of RBC transfusions respectively in combination with other risk factors on the outcome we performed a multivariate logistic regression analysis. 16 risk factors for weaning failure and hospital mortality were identified through an extensive literature research. Beside the German S2k-Guideline for Prolonged Weaning, systematic reviews and articles were analysed. In consideration of their perceived importance for the outcome, their interest in relation to the research question and the availability of data, the predictive risk factors were selected by group consent of two physicians who are experienced in the treatment of patients undergoing prolonged weaning. The examined factors included age, gender, the sum of SAPS II and TISS on admission at ICU and at WEA, Hb concentration on admission at ICU and at WEA, mean Hb concentration during WEA stay, duration of MV, RBC transfusions at ICU and at WEA, usage of vasopressors and RRT during WEA stay and presence of comorbidities (coronary heart disease, cardiovascular risk factors and chronic obstructive pulmonary disease (COPD)) and the patient’s treating department (surgical or medical). In a first step, all parameters without relevant influence on the probability for a weaning failure were removed using a backward elimination approach with a significance level of α=0.2. Selected variables were inserted into the final model. The null hypothesis that the OR is OR=1 for all influence variables was tested with a Wald test at the 0.05 significance level. The linearity in the logit was tested graphically by plotting the observed values of continuous variables against the predicted logits of outcome parameters. The possible presence of multicollinearity was discussed using a correlation matrix making sure that each pair of variables had a Pearson correlation coefficient below 0.8 and a variance inflation factor below 2.5 to exclude excessive multicollinearity.

**RESULTS**

**Clinical characteristics**

During the observed period, 242 patients were admitted to the WEA, of whom 58 patients met exclusion criteria. The analysed dataset consisted of 184 patients. Thirty-six patients could not be weaned successfully, of whom 34 patients died in hospital (see figure 2) resulting in a
hospital mortality rate of 18.5%. The mean length of stay on WEA was 24.0 (median 20) days with a mean MV duration of 336.7 hours (median 253). Patients who required no transfusions could be discharged from the WEA relevantly earlier compared with the transfusion group (mean: 16.5 vs 31.8; median: 15 vs 25.5) and required dramatically less time of MV until they could be liberated from it (184.30 vs 495.90; median: 156.5 vs 363) (see figure 3). The full clinical characteristics are given in table 1.

Hb and RBC transfusions
Already at admission to the ICU, 72.28% of the analysed population fulfilled the criteria of anaemia. During the period of ICU treatment, the mean Hb value dropped about 22.9±23.3 g/dL. At the end of the WEA stay, there was only one non-anaemic patient left.

While during acute critical care on ICU 139 patients, that is, 75.5% of the total population required RBC transfusion, this proportion decreased to 90 patients (48.9%) during treatment on WEA. Patients transfused on WEA, received 4.38 RBC units in the mean during WEA stay. These patients had a significantly lower mean Hb value (86.3±5.3 g/L) compared with those without need for RBC transfusion (95.8±10.5 g/L).

Organ dysfunction
The patients requiring RBC transfusion showed findings indicating a severer condition in many organ systems. In addition to a longer duration of MV and a lower mean Hb value, which were already described above, the proportion of patients requiring RRT during weaning was also most pronounced in the transfusion group (2.1% vs 28.9%). A vast majority of non-transfused patients did not require vasopressors (71.3%) during their stay on WEA while a similar proportion in the transfusion group showed a need for vasopressors (74.4%), with 50% of transfused patients even requiring high doses. Moreover, the sum of the SAPS II and the TISS score at admission on WEA representing the general severity of disease was 4.12 (CI 1.73; 6.52) points higher in transfused patients (see figure 4).

Multivariate regression analysis
Dependent factor: weaning failure
To analyse the influence of certain risk factors on weaning failure as the primary endpoint, 16 potential risk factors (see Methods) were integrated into a multivariate logistic regression model. The null hypothesis that all ORs are OR=1 for all influence variables was rejected (Wald test=27.01, p<0.0001). After removal of the irrelevant parameters using a backward elimination approach, four parameters remained: (1) need for vasopressors on WEA, (2) duration of MV, (3) transfusion of RBC on WEA and (4) Hb concentration on admission WEA. The ORs and 95% CI are given in table 2.

When the categorical variables for RBC transfusion (yes/no) were substituted by the absolute number of RBC units as input variables before the backward elimination, this caused some changes in the resulting model: the number of RBC units persisted in the final model due to the α=0.2 of the selection process but did not reach the stricter p value of <0.05 missing the significance level (OR 0.902; 95% CI 0.789 to 1.031, p=0.1292). Further, the variable ‘Hb value at admission on WEA’ was substituted by the variable ‘RRT on WEA’.

Dependent factor: hospital mortality
For the secondary endpoint, namely hospital mortality, another multivariate regression model was developed. When hospital mortality was used as dependent variable, the composition of risk factors changed. Despite its relevant impact on weaning failure, neither RBC transfusions on ICU nor on WEA seemed to have a relevant impact on mortality in our cohort and thus were removed early during the elimination process. The respective variables, the ORs and 95% CIs are given in table 3.

DISCUSSION
Meaning of our findings
In our observational study, we found that nearly 50% of the included patients undergoing prolonged weaning from MV on a specialised weaning unit required one or
### Table 1: Clinical characteristics of the total population and subdivided according to received red blood cell transfusion on WEA

| Parameter                              | Total n=184 (100%) | Not transfused n=94 (51.09%) | Transfused n=90 (48.91%) | MD (95% CI) or OR (95% CI) |
|----------------------------------------|-------------------|------------------------------|--------------------------|---------------------------|
| Age (years)                            | 69.14±11.74       | 67.64±12.43                  | 70.70±10.81              | −3.06 (−6.46 to 0.33)     |
| Male gender                            | 139 (75.54)       | 79 (84.04)                   | 60 (66.67)               | 2.63 (1.30 to 5.33)       |
| Length of stay                         |                   |                              |                          |                           |
| ICU before WEA (d)                     | 18.88±12.69       | 17.15±10.23                  | 20.68±14.67              | −3.53 (−7.23 to 0.17)     |
| WEA (d)                                | 23.99±17.43       | 16.49±9.19                   | 31.82±20.37              | −15.33 (−19.98 to −10.69) |
| MV duration (h)                        |                   |                              |                          |                           |
| Total                                  | 762.09±443.24     | 561.77±241.20                | 971.32±506.47            | −409.6 (−526.1 to −293.0) |
| On WEA                                 | 336.71±333.36     | 184.30±130.48                | 495.90±400.68            | −311.6 (−399.5 to −223.7) |
| Death                                  |                   |                              |                          |                           |
| Total*                                 | 34 (18.48)        | 7 (7.45)                     | 27 (30)                  | 5.33 (2.18 to 13.00)      |
| On WEA                                 | 25 (13.59)        | 5 (5.32)                     | 20 (22.22)               | 5.09 (1.82 to 14.23)      |
| Weaning outcome                        |                   |                              |                          |                           |
| Success (3a)                           | 148 (80.43)       | 87 (92.55)                   | 61 (67.78)               | 0.17 (0.07 to 0.41)       |
| Failure                                | 36 (19.57)        | 7 (7.45)                     | 29 (32.22)               | 5.91 (2.43 to 14.36)      |
| 3b                                     | 2 (1.09)          | 0                            | 2 (2.22)                 |                           |
| 3c                                     | 34 (18.48)        | 7 (7.45)                     | 27 (30)                  |                           |
| Clinical department                    |                   |                              |                          |                           |
| Internal medicine                      | 65 (35.33)        | 40 (42.55)                   | 25 (27.78)               | 0.52 (0.28 to 0.96)       |
| Surgery                                | 119 (64.67)       | 54 (57.45)                   | 65 (72.22)               | 1.93 (1.04 to 3.57)       |
| Cardiac and thoracic surgery           | 64 (34.78)        | 26 (27.66)                   | 38 (42.22)               |                           |
| Neurosurgery                           | 17 (9.24)         | 13 (13.83)                   | 4 (4.44)                 |                           |
| Abdominal surgery                      | 12 (6.52)         | 2 (2.13)                     | 10 (11.11)               |                           |
| Other surgical discipline              | 26 (13.98)        | 13 (13.83)                   | 13 (14.44)               |                           |
| Hb values                              |                   |                              |                          |                           |
| On admission ICU                       | 109.7±24.9        | 116.6±25.6                   | 102.5±22.1               | 14.2 (7.2 to 21.1)        |
| On admission WEA                       | 86.8±10.7         | 91.1±11.1                    | 82.4±8.0                 | 8.8 (6.0 to 11.6)         |
| Last value on WEA                      | 90.5±12.4         | 94.8±12.6                    | 86.0±10.4                | 8.8 (5.5 to 12.2)         |
| Anaemia                                |                   |                              |                          |                           |
| On admission ICU                       | 133 (72.28)       | 57 (60.64)                   | 76 (84.44)               | 3.52 (1.74 to 7.13)       |
| On admission WEA                       | 182 (98.91)       | 92 (97.87)                   | 90 (100)                 | n/a                       |
| At discharge WEA                       | 183 (99.46)       | 93 (98.94)                   | 90 (100)                 | n/a                       |
| Patients receiving RBC transfusion    |                   |                              |                          |                           |
| On ICU                                 | 139 (75.54)       | 61 (64.89 %)                 | 78 (86.67)               | 3.52 (1.68 to 7.38)       |
| On WEA                                 | 90 (48.91)        | -/-                          | 90 (100)                 | n/a                       |
| RBC count                              |                   |                              |                          |                           |
| On ICU before WEA                      | 4.86±6.37         | 3.19±4.35                    | 6.60±7.59                | −3.41 (−5.22 to −1.60)    |
| On WEA                                 | 2.14±3.76         | 0                            | 4.38±4.37                | −4.38 (−5.30 to −3.46)    |
| Hb mean value on WEA                   | 91.2±9.6          | 95.8±10.5                    | 86.3±5.3                 | 9.5 (7.1 to 11.9)         |
| SAPS und TISS                          |                   |                              |                          |                           |
| On admission ICU                       | 37.68±9.15        | 36.20±9.14                   | 39.22±8.94               | −3.02 (−5.65 to −0.39)    |
| TISS                                   | 14.85±6.49        | 14.06±6.08                   | 15.67±6.82               | −1.60 (−3.48 to 0.28)     |
| SAPS II+TISS                           | 52.39±13.54       | 50.27±12.97                  | 54.61±13.84              | −4.35 (−8.25 to −0.45)    |

Continued
### Table 1 Continued

| Parameter                          | Total n=184 (100%) | Not transfused n=94 (51.09%) | Transfused n=90 (48.91%) | MD (95% CI) or OR (95% CI) |
|------------------------------------|--------------------|-------------------------------|--------------------------|---------------------------|
| **On admission WEA**               |                    |                               |                          |                           |
| SAPS II                            | 32.34±7.99         | 30.66±7.34                    | 34.09±8.31               | −3.43 (−5.71 to −1.15)    |
| TISS                               | 10.24±1.78         | 9.95±1.79                     | 10.54±1.73               | −0.60 (−1.11 to −0.09)    |
| SAPS II+TISS                       | 42.53±8.47         | 40.51±7.59                    | 44.63±8.87               | −4.12 (−6.52 to −1.73)    |
| **Preexisting diseases**           |                    |                               |                          |                           |
| Coronary heart disease             | 103 (55.98)        | 49 (52.13)                    | 54 (60)                  | 1.38 (0.77 to 2.47)       |
| CVRF                               | 158 (85.87)        | 78 (82.89)                    | 80 (88.89)               | 1.64 (0.70 to 3.84)       |
| Implanted heart valve              | 38 (20.65)         | 16 (17.02)                    | 22 (24.44)               | 1.58 (0.77 to 3.25)       |
| COPD                               | 42 (22.83)         | 16 (17.02)                    | 26 (28.89)               | 1.98 (0.98 to 4.01)       |
| GOLD I                             | 2 (1.09)           | 1 (1.06)                      | 1 (1.11)                 |                           |
| GOLD II                            | 6 (3.26)           | 2 (2.13)                      | 4 (4.44)                 |                           |
| GOLD III                           | 6 (3.26)           | 1 (1.06)                      | 5 (5.56)                 |                           |
| GOLD IV                            | 12 (6.52)          | 4 (4.26)                      | 8 (8.89)                 |                           |
| GOLD undetermined                  | 13 (7.07)          | 6 (6.38)                      | 7 (7.78)                 |                           |
| Asthma                             | 4 (2.17)           | 3 (3.19)                      | 1 (1.11)                 | 0.34 (0.04 to 3.34)       |
| Neuromuscular disease              | 14 (7.61)          | 8 (8.51)                      | 6 (6.67)                 | 0.77 (0.26 to 2.31)       |
| **Course of treatment**            |                    |                               |                          |                           |
| ECMO required (before WEA)         | 6 (3.26)           | 5 (5.32)                      | 1 (1.11)                 | 0.20 (0.02 to 1.75)       |
| OP on cardiopulmonary bypass       | 62 (33.70)         | 24 (25.53)                    | 38 (42.52)               | 2.13 (1.14 to 3.98)       |
| Pulmonary embolism                 | 4 (2.17)           | 2 (2.13)                      | 2 (2.22)                 | 1.05 (0.14 to 7.58)       |
| **Anticoagulants**                 |                    |                               |                          |                           |
| Heparine prophylactic dose         | 71 (38.59)         | 28 (29.79)                    | 43 (47.78)               | 2.16 (1.77 to 3.95)       |
| Heparine therapeutic dose          | 82 (44.57)         | 30 (31.91)                    | 52 (57.78)               | 2.92 (1.60 to 5.33)       |
| LMWH prophylactic dose             | 82 (44.57)         | 50 (53.19)                    | 32 (35.56)               | 0.49 (0.27 to 0.88)       |
| LMWH therapeutic dose              | 38 (20.65)         | 22 (23.40)                    | 16 (17.78)               | 0.71 (0.34 to 1.46)       |
| Argatroban proph. dose             | 1 (0.54)           | 0                             | 1 (1.11)                 | n/a                       |
| Argatroban ther. dose              | 4 (2.17)           | 2 (2.13)                      | 2 (2.22)                 | 1.05 (0.14 to 7.58)       |
| OAC                                | 13 (7.07)          | 5 (5.32)                      | 8 (8.89)                 | 1.74 (0.55 to 5.52)       |
| NOAC                               | 2 (1.09)           | 1 (1.06)                      | 1 (1.11)                 | 1.05 (0.06 to 16.96)      |
| Acetylsalicylic acid only          | 79 (43.93)         | 37 (39.36)                    | 42 (46.67)               | 1.35 (0.75 to 2.42)       |
| P2Y Antagonist only                | 4 (2.17)           | 1 (1.06)                      | 3 (3.33)                 | 3.21 (0.33 to 31.42)      |
| DAPT                               | 37 (20.11)         | 20 (21.28)                    | 17 (18.89)               | 0.86 (0.42 to 1.78)       |
| **Vasopressors**                   |                    |                               |                          |                           |
| None                               | 90 (48.91)         | 67 (71.28)                    | 23 (25.56)               | 0.14 (0.07 to 0.27)       |
| Norepinephrine                     | 94 (51.09)         | 27 (28.72)                    | 67 (74.44)               | 7.23 (3.77 to 13.86)      |
| <0.05 µg/kg/min                    | 12 (6.52)          | 5 (5.32)                      | 7 (7.78)                 |                           |
| 0.05–0.1 µg/kg/min                 | 22 (11.96)         | 7 (7.45)                      | 15 (16.67)               |                           |
| ≥0.1 µg/kg/min (or other vasopressors) | 60 (32.61)     | 15 (15.96)                    | 45 (50)                  |                           |
| Renal replacement therapy          | 28 (15.22)         | 2 (2.13)                      | 26 (28.89)               | 18.69 (4.28 to 81.54)     |

Data are given as mean±SD or n (%). Differences in means were calculated as non-transfused group minus transfused group. *Including fatal cases after discharge from WEA during the same hospital stay.

COPD, chronic obstructive pulmonary disease; CVRF, cardiovascular risk factor; DAPT, dual antiplatelet therapy; ECMO, extracorporeal membrane oxygenation; GOLD, Global Initiative for Chronic Obstructive Lung Disease; Hb, haemoglobin; ICU, intensive care unit; LMWH, low molecular weight heparine; MD, mean difference; MV, mechanical ventilation; n/a, not applicable; NOAC, novel oral anticoagulants; OAC, oral anticoagulant; OP, operation; RBC, red blood cell; SAPS, Simplified Acute Physiology Score; TISS, Therapeutic Intervention Scoring System; WEA, weaning unit.
more RBC transfusion during the weaning procedure. Patients who failed to be weaned successfully received significantly more RBC transfusions. In a multivariate analysis, RBC transfusions were significantly associated with weaning failure, but not mortality. The mean Hb value did not have a significant influence on the outcome. Given these results, it is rather confusing that in multivariate analysis, a higher Hb value at admission on WEA appeared to be associated with weaning failure. It should be noted, however, that this parameter only meets the much less stringent alpha of 0.2 used in feature selection and not the classical threshold for statistical significance of 0.05. The CI therefore clearly extends into the range that would allow a contrary conclusion, leaving the relevance of this result unclear.

A remarkable result of our study was that patients in the transfusion group showed characteristics that can be interpreted as a higher disease severity in several different aspects, indicated by higher scores of SAPS II and TISS, but also a higher requirement for vasopressors and RRT beyond the patients requiring RBC transfusion. According to this severe disease state, transfused patients showed a consistently lower mean Hb value than the non-transfused group. Obviously, the patients who did not require RBC transfusions were able to build up a higher Hb level without external support than the transfused group who received additional erythrocytes from external. Summarising our results, the question arises whether the debate of the optimal Hb level in patients undergoing prolonged weaning is not an illegitimate truncation. Research that focuses on an optimal Hb value for the weaning process may tend to ignore the additional problems which prevent a patient’s recovery and aim to treat rather a symptom than the underlying problem. Possibly, the need for transfusions rather forms a surrogate parameter for a persistency of a critical disease status, which encompasses not only an impaired haematopoiesis but also, for example, a failure of vaso- motors or an insufficient kidney function. Thus, our results need to be interpreted with caution. In addition, the length of stay of transfused patients on the weaning ward was significantly longer than in the group without transfusion. This exposure interval could introduce bias, since the repeated diagnostic blood samples could cause anaemia and finally lead to RBC transfusion. The long duration of treatment could also, if perceived by the treating physicians as a failure of the previous therapy, lead them to consider further therapeutic options. Thus, the conscious or unconscious opinion that RBC transfusions might be beneficial for the patient may also play a role, an attitude whose incorrectness still persists among physicians despite growing evidence to the contrary.

### Comparison with other studies

Until today, the impact of transfusions on the outcome of patients in prolonged weaning is unknown. Patients with COPD typically show an increased work of breathing, which exceeds the respiratory muscle capacity and thus hampers an easy MV liberation. In this patient group, it was shown that RBC transfusion could reduce work of breathing and mean minute ventilation, while this effect was shown that RBC transfusion could reduce work of breathing and mean minute ventilation, while this effect in patients without pulmonary disease was lacking. According to that, Schönhofer et al reported a cases series of five anaemic COPD patients who were weaned successfully after increasing their Hb value. In a retrospective study including 138 difficult-to-wean patients, Lai et al found that patients with an Hb value above 80 g/L were significantly more likely to be successfully weaned compared with those with an Hb value below that threshold. In the same study, RBC transfusions were associated with weaning failure if they were given to patients with an Hb value above 100 g/L. Below that value they

### Table 2 Multivariate regression analysis, dependent variable: weaning failure

| Variable                        | OR   | 95% CI           | P value |
|---------------------------------|------|------------------|---------|
| RBC transfusion on WEA          | 3.243| 1.028 to 10.230  | 0.045   |
| Need for vasopressors on WEA    | 1.557| 1.093 to 2.217   | 0.014   |
| Hb value at admission on WEA    | 1.375| 0.887 to 2.132   | 0.155   |
| Duration of MV                  | 1.001| 1.000 to 1.002   | 0.027   |

Hb, haemoglobin; MV, mechanical ventilation; RBC, red blood cell; WEA, weaning unit.
and has a considerably poor outcome. This link could offer an explanation for the apparent coincidence of lower Hb value, repeated need for RBC transfusions and poor outcome.

Strengths and limitations

In our study, we focused on patients in prolonged weaning admitted to a specialised weaning unit. These patients suffer from the most severe form of respiratory insufficiency and show several characteristics that may separate them from other ICU patients. The evidence in this field is insufficient and the role of Hb value and RBC transfusion is in our opinion scientifically and clinically relevant. By limiting the inclusion to patients from a specialised unit, it was possible to generate a profound population which was large especially compared with previous observational studies. This allowed us more complex statistical analyses like multivariate regression analyses. Nevertheless, it must be noted that the number of events per included variable are below the widely recommended lower limit of 5. Although there are authors who point out that the current evidence supporting EPV rules for binary logistic regression is weak and other factors like the total sample size also have an influence, we must acknowledge that our analysis may be underpowered to some extent.

Regarding the RBC transfusions, it should be noted that there were no strict rules or threshold values that would have led directly to a transfusion. The German guideline only provided basic orientation, which gave the attending physician a relatively large degree of freedom in making the indication. Information about the reasons for a physician’s decision to transfuse a certain patient in a certain situation, were lacking. Thus, it cannot be ruled out that the possibly unconscious—perception of the patient’s poor condition may have influenced the decision for a transfusion. Due to the retrospective character of our study, several parameters, which would have been interesting, for example, for the correlation between RBC transfusions and infectious complications, were not available and prohibited an examination of this aspect. Missing data also led to exclusion of 58 patients due to transferral from or to external hospitals. Although the proportion of transfused patients in this excluded group was nearly identical to that of included patients, the weaning success rate was lower among the excluded patients (62% excluding vs 80% including) from whom a final weaning outcome was known. However, the introduction of bias through this event is as well possible. Finally, it cannot be ruled out that there is an influence of unmeasured or residual confounding from important factors that were not measured or included, especially given the complexity of the population. This is also due to the fact that risk factors included to the regression analysis were ultimately chosen via a consensus process between two physicians.

In the end, it must be considered that the explanatory power of a retrospective monocentric study is low. These studies are regularly prone to relevant bias and can only offer associations. In addition, if these associations showed no effect. In 2019, Ghiani et al published an observational study on the influence of RBC transfusions in 378 prolonged weaning patients. Their results were similar with our findings within the usual range of variation. Deviating from our results, they did not find an association between RBC transfusion and weaning failure, but a trend to increased mortality in the transfusion group which was vice versa in our population. In agreement to our findings, they showed a higher disease severity within the transfusion group, as well. Several authors reported that a liberal transfusion strategy was not shown to be beneficial in MV patients, although the MV durations in these studies were regularly shorter and thus not comparable to patients in prolonged weaning. At first sight, our results seem to support this negative view on RBC transfusions. But as already pointed out, it is at least questionable whether the undesired outcome of the transfused patients in the observed population has a direct causal relationship with the received RBC transfusion. An important factor for anaemia in critically ill patients is a persisting systemic inflammation, which was already shown to impair erythropoiesis. Such an inflammatory process contributes to chronic critical illness which is common among long-term MV patients and has a considerably poor outcome. This link could offer an explanation for the apparent coincidence of lower Hb value, repeated need for RBC transfusions and poor outcome.

Table 3  Multivariate regression analysis, dependent variable: hospital mortality

| Variable                                      | OR     | 95% CI          | P value |
|-----------------------------------------------|--------|-----------------|---------|
| Internal medicine patient                    | 3.392  | 1.098 to 10.474 | 0.034   |
| RRT on WEA                                    | 2.224  | 0.750 to 6.594  | 0.150   |
| Need for vasopressors on WEA                  | 1.972  | 1.327 to 2.932  | <0.001  |
| SAPS II+TISS at admission on WEA              | 1.057  | 0.988 to 1.132  | 0.108   |
| Age                                           | 1.049  | 0.994 to 1.108  | 0.084   |
| Duration of MV                                | 1.001  | 1.000 to 1.002  | 0.067   |
| Hb value at admission on ICU                  | 0.807  | 0.654 to 0.995  | 0.044   |

Hb, haemoglobin; ICU, intensive care unit; MV, mechanical ventilation; RRT, renal replacement therapy; SAPS II, Simplified Acute Physiology Score II; TISS, Therapeutic Intervention Scoring System; WEA, weaning unit.

By limiting the inclusion to patients from a specialised weaning unit, it was possible to generate a profound population which was large especially compared with previous observational studies. This allowed us more complex statistical analyses like multivariate regression analyses. Nevertheless, it must be noted that the number of events per included variable are below the widely recommended lower limit of 5. Although there are authors who point out that the current evidence supporting EPV rules for binary logistic regression is weak and other factors like the total sample size also have an influence, we must acknowledge that our analysis may be underpowered to some extent.

Regarding the RBC transfusions, it should be noted that there were no strict rules or threshold values that would have led directly to a transfusion. The German guideline only provided basic orientation, which gave the attending physician a relatively large degree of freedom in making the indication. Information about the reasons for a physician’s decision to transfuse a certain patient in a certain situation, were lacking. Thus, it cannot be ruled out that the possibly unconscious—perception of the patient’s poor condition may have influenced the decision for a transfusion. Due to the retrospective character of our study, several parameters, which would have been interesting, for example, for the correlation between RBC transfusions and infectious complications, were not available and prohibited an examination of this aspect. Missing data also led to exclusion of 58 patients due to transferral from or to external hospitals. Although the proportion of transfused patients in this excluded group was nearly identical to that of included patients, the weaning success rate was lower among the excluded patients (62% excluding vs 80% including) from whom a final weaning outcome was known. However, the introduction of bias through this event is as well possible. Finally, it cannot be ruled out that there is an influence of unmeasured or residual confounding from important factors that were not measured or included, especially given the complexity of the population. This is also due to the fact that risk factors included to the regression analysis were ultimately chosen via a consensus process between two physicians.

In the end, it must be considered that the explanatory power of a retrospective monocentric study is low. These studies are regularly prone to relevant bias and can only offer associations. In addition, if these associations showed no effect. In 2019, Ghiani et al published an observational study on the influence of RBC transfusions in 378 prolonged weaning patients. Their results were similar with our findings within the usual range of variation. Deviating from our results, they did not find an association between RBC transfusion and weaning failure, but a trend to increased mortality in the transfusion group which was vice versa in our population. In agreement to our findings, they showed a higher disease severity within the transfusion group, as well. Several authors reported that a liberal transfusion strategy was not shown to be beneficial in MV patients, although the MV durations in these studies were regularly shorter and thus not comparable to patients in prolonged weaning. At first sight, our results seem to support this negative view on RBC transfusions. But as already pointed out, it is at least questionable whether the undesired outcome of the transfused patients in the observed population has a direct causal relationship with the received RBC transfusion. An important factor for anaemia in critically ill patients is a persisting systemic inflammation, which was already shown to impair erythropoiesis. Such an inflammatory process contributes to chronic critical illness which is common among long-term MV patients and has a considerably poor outcome. This link could offer an explanation for the apparent coincidence of lower Hb value, repeated need for RBC transfusions and poor outcome.

Table 3  Multivariate regression analysis, dependent variable: hospital mortality

| Variable                                      | OR     | 95% CI          | P value |
|-----------------------------------------------|--------|-----------------|---------|
| Internal medicine patient                    | 3.392  | 1.098 to 10.474 | 0.034   |
| RRT on WEA                                    | 2.224  | 0.750 to 6.594  | 0.150   |
| Need for vasopressors on WEA                  | 1.972  | 1.327 to 2.932  | <0.001  |
| SAPS II+TISS at admission on WEA              | 1.057  | 0.988 to 1.132  | 0.108   |
| Age                                           | 1.049  | 0.994 to 1.108  | 0.084   |
| Duration of MV                                | 1.001  | 1.000 to 1.002  | 0.067   |
| Hb value at admission on ICU                  | 0.807  | 0.654 to 0.995  | 0.044   |

Hb, haemoglobin; ICU, intensive care unit; MV, mechanical ventilation; RRT, renal replacement therapy; SAPS II, Simplified Acute Physiology Score II; TISS, Therapeutic Intervention Scoring System; WEA, weaning unit.
are real and not caused by potential biases, they are not necessarily due to causal effects. Nevertheless, they can form the base to generate new hypotheses for prospective observational, or even randomised controlled trials.

Further research

The results of our retrospective analysis raise a number of questions which should be addressed in future prospective, ideally randomised controlled studies. The need for RBC transfusions seemed to be associated with a persisting critical state of disease, which negatively influences several organ functions contributing to a low Hb value, as well. Further research should focus on a more detailed characterisation of this critical condition that can be inferred from our results and its underlying processes and, in the case that its existence can be demonstrated, seek appropriate therapeutic approaches. Ultimately, our study cannot answer the question of whether patients in prolonged weaning benefit from actively increasing their Hb levels, since the transfusions observed in our study were not even sufficient to raise the Hb value of the transfusion group to the level of the non-transfused patients. This point still requires further examination, as well.

Acknowledgements

We would like to thank Marc Kaiser for his contribution in the conception of the study and his preparation of data extraction.

Contributors

SJF und JB designed the study. SJF acquired and analysed the data and drafted the manuscript. All authors contributed to the interpretation of the data and revised the manuscript critically. All authors read and approved the final version of the manuscript. SJF acts as guarantor for this study.

Funding

The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests

None declared.

Patient and public involvement

Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication

Not applicable.

Ethics approval

This study was approved by the local ethical review board (EK 122/13) Ethics Committee, Faculty of Medicine, RWTH Aachen, Aachen, Germany). Due to the retrospective character of the study, the need for an informed consent was waived.

Provenance and peer review

Not commissioned; externally peer reviewed.

Data availability statement

Data are available on reasonable request. The patient datasets, which were generated and analysed in this study, are not publicly available due to medical confidentiality. They are available from the corresponding author in deidentified form on reasonable request.

Open access

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD

Sebastian Johannes Fritsch http://orcid.org/0000-0002-8350-8584

REFERENCES

1. Boles J-M, Blon J, Connors A, et al. Weaning from mechanical ventilation. Eur Respir J 2007;29:1033–56.
2. Schönhofer B, Geiseler J, Dellweg D, et al. [Prolonged Weaning - 52k-Guideline Published by the German Respiratory Society]. Pneumologie 2019;73(7):814.
3. Thomas J, Jensen L, Nahrišek S, et al. Anemia and blood transfusion practices in the critically ill: a prospective cohort review. Heart Lung 2010;39:217–25.
4. Walsh TS, Saleh E-D. Anemia during critical illness. Br J Anaesth 2006;97:278–91.
5. Cavalcante Dos Santos E, Orbeogozo D, Mongkolpun W, et al. Systematic review and meta-analysis of effects of transfusion on hemodynamic and oxygenation variables. Crit Care Med 2020;48:241–8.
6. Viress N, Silyge G, Aubier M, et al. Regional blood flow distribution in dog during induced hypotension and low cardiac output: spontaneous breathing versus artificial ventilation. J Clin Invest 1983;72:935–47.
7. Taylor RW, O’Brien J, Trottier SJ, et al. Red blood cell transfusions and nosocomial infections in critically ill patients. Crit Care Med 2006;34:2302–9. quiz 29.
8. Nederpelt CJ, El Hechi M, Parks J, et al. The dose-dependent relationship between blood transfusions and infections after trauma: a population-based study. J Trauma Acute Care Surg 2020;89:51–7.
9. Shorr AF, Duh M-S, Kelly KM, et al. Red blood cell transfusion and ventilator-associated pneumonia: a potential link? Crit Care Med 2004;32:662–74.
10. Rothe JM, Dimcheff DE, Blumberg N, et al. Health care-associated infection after red blood cell transfusion: a systematic review and meta-analysis. JAMA 2014;311:1317–26.
11. Ghiani A, Sainis A, Sainis G, et al. Anemia and red blood cell transfusion practice in prolonged mechanically ventilated patients admitted to a specialized weaning center: an observational study, BMC Pulm Med 2019;19:250.
12. Hendrickson JE, Hillyer CD. Noninfectious serious hazards of transfusion. Anesth Analg 2006;103:759–69.
13. Gong MN, Thompson BT, Williams P, et al. Clinical predictors of and mortality in acute respiratory distress syndrome: potential role of red cell transfusion. Crit Care Med 2005;33:1191–8.
14. Zilberberg MD, Shorr AF. Effect of a restrictive transfusion strategy on transfusion-attributable severe acute complications and costs in the US ICUs: a model simulation. BMJ Health Serv Res 2007:7:138.
15. Yilmaz M, Keegan MT, Iscimen R, et al. Toward the prevention of acute lung injury: protocol-guided limitation of large tidal volume ventilation and inappropriate transfusion. Crit Care Med 2007;35:1660–6. quiz 67.
16. Napolitano L. Cumulative risks of early red blood cell transfusion. J Trauma 2006;60:S26–34.
17. Wang JK, Klein HG. Red blood cell transfusion in the treatment and management of anemia: the search for the elusive transfusion trigger. Vox Sang 2010;98:2–11.
18. Klein HG, Spahn DR, Carson JL. Red blood cell transfusion in clinical practice. Lancet 2007;370:415–26.
19. Maclntyre NR, Cook DJ, Ely EW, et al. Evidence-Based guidelines for weaning and discontinuing ventilatory support: a collective Task force facilitated by the American College of chest physicians; the American association for respiratory care; and the American College of critical care medicine. Chest 2001;120:375S–95.
20. von Elm E, Altman DG, Egger M, et al. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007;335:806–8.
21. World Health Organization. Nutritional anaemias: report of a WHO scientific group [meeting held in Geneva from 13 to 17 March 1967]. World Health Organization, 1968.
22. Dettmer MR, Damuth E, Zarbick S, et al. Prognostic factors for long-term mortality in critically ill patients treated with prolonged mechanical ventilation: a systematic review. Crit Care Med 2017;45:69–74.
23. Warnke G, Heine A, Müller-Heinrich A, et al. Predictors of survival after prolonged weaning from mechanical ventilation. J Crit Care 2020;60:212–7.
24. Baptista RA, Sarmento FJ, da Silva KR, et al. Predictive factors of weaning from mechanical ventilation and extubation outcome: a systematic review. J Crit Care 2018;48:56–62.
25. WeanNet Study Group. [WeanNet: The network of weaning studies in intensive care]. JAMA 2016;141:e166–72.
26. Yang P-H, Hung J-Y, Yang C-J, et al. Successful weaning predictors in a respiratory care center in Taiwan. Kaohsiung J Med Sci 2008;24:85–91.
27. Lai Y-C, Ruan S-Y, Huang C-T, et al. Hemoglobin levels and weaning outcome of mechanical ventilation in difficult-to-wean patients: a retrospective cohort study. PLoS One 2013;8:e73743–434.
28. Midi H, Sarkar SK, Rana S. Collinearity diagnostics of binary logistic regression model. *Journal of Interdisciplinary Mathematics* 2010;13:253–67.

29. Chant C, Wilson G, Friedrich JO. Anemia, transfusion, and phlebotomy practices in critically ill patients with prolonged ICU length of stay: a cohort study. *Crit Care* 2006;10:R140.

30. Soril LJJ, Noseworthy TW, Stelfox HT, et al. Facilitators of and barriers to adopting a restrictive red blood cell transfusion practice: a population-based cross-sectional survey. *CMAJ Open* 2019;7:E252–7.

31. von Babo M, Chmiel C, Müggler SA, et al. Transfusion practice in anemic, non-bleeding patients: cross-sectional survey of physicians working in general internal medicine teaching hospitals in Switzerland. *PLoS One* 2018;13:e0191752.

32. Schönhofer B, Wenzel M, Geibel M, et al. Blood transfusion and lung function in chronically anemic patients with severe chronic obstructive pulmonary disease. *Crit Care Med* 1998;26:1824–8.

33. Schönhofer B, Böhrer H, Köhler D. Blood transfusion facilitating difficult weaning from the ventilator. *Anaesthesia* 1998:53:181–4.

34. Hébert PC, Blajchman MA, Cook DJ, et al. Do blood transfusions improve outcomes related to mechanical ventilation? *Chest* 2001;119:1850–7.

35. Walsh TS, Boyd JA, Watson D, et al. Restrictive versus liberal transfusion strategies for older mechanically ventilated critically ill patients: a randomized pilot trial. *Crit Care Med* 2013;41:2354–63.

36. Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. *Blood* 2019;133:40–50.

37. Loftus TJ, Mira JC, Stortz JA, et al. Persistent inflammation and anemia among critically ill septic patients. *J Trauma Acute Care Surg* 2019;86:260–7.

38. Bible LE, Pasupuleti LV, Alzate WD, et al. Early propranolol administration to severely injured patients can improve bone marrow dysfunction. *J Trauma Acute Care Surg* 2014;77:54–60. discussion 59-60.

39. Cox CE. Persistent systemic inflammation in chronic critical illness. *Respir Care* 2012;57:859–66.

40. Marchioni A, Fantini R, Antenora F, et al. Chronic critical illness: the price of survival. *Eur J Clin Invest* 2015;45:1341–9.

41. Perren A, Brochard L. Managing the apparent and hidden difficulties of weaning from mechanical ventilation. *Intensive Care Med* 2013;39:1885–95.

42. van Smeden M, de Groot JAH, Moons KGM, et al. No rationale for 1 variable per 10 events criterion for binary logistic regression analysis. *BMC Med Res Methodol* 2016;16:163.